TY - JOUR
T1 - Total, dialyzable, and nondialyzable postabsorptive hydroxyproline. Values in patients with cancer
AU - Niell, H. B.
AU - Palmieri, G. M.
AU - Neely, C. L.
AU - Maxwell, T. A.
AU - Hopkins, S. C.
AU - Soloway, M. S.
PY - 1983/11/26
Y1 - 1983/11/26
N2 - The postabsorptive urinary total (T), dialyzable (D), and nondialyzable (ND) hydroxyproline (HYPRO) tests were evaluated to determine whether the patterns of excretion varied according to the predominance of osteoblastic v osteolytic bone involvement in 58 patients with neoplastic disease. In patients with osteolytic lesions from multiple myeloma, elevated T and D levels with normal ND HYPRO values were observed, along with elevated D/ND ratios. In prostate cancer, the T, D, and ND values were all elevated and the D/ND ratio was normal. Patients with Hodgkin's disease had elevated T, D, and ND HYPRO levels, and the D/ND ratio was in the range of patients with prostate cancer. The data suggest that these collagen markers may be useful in the long-term evaluation of these neoplasms in patients.
AB - The postabsorptive urinary total (T), dialyzable (D), and nondialyzable (ND) hydroxyproline (HYPRO) tests were evaluated to determine whether the patterns of excretion varied according to the predominance of osteoblastic v osteolytic bone involvement in 58 patients with neoplastic disease. In patients with osteolytic lesions from multiple myeloma, elevated T and D levels with normal ND HYPRO values were observed, along with elevated D/ND ratios. In prostate cancer, the T, D, and ND values were all elevated and the D/ND ratio was normal. Patients with Hodgkin's disease had elevated T, D, and ND HYPRO levels, and the D/ND ratio was in the range of patients with prostate cancer. The data suggest that these collagen markers may be useful in the long-term evaluation of these neoplasms in patients.
UR - http://www.scopus.com/inward/record.url?scp=0020515062&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020515062&partnerID=8YFLogxK
U2 - 10.1001/archinte.143.10.1925
DO - 10.1001/archinte.143.10.1925
M3 - Article
C2 - 6625779
VL - 143
SP - 1925
EP - 1927
JO - JAMA Internal Medicine
JF - JAMA Internal Medicine
SN - 2168-6106
IS - 10
ER -